AROA Business Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Aroa Biosurgery Ltd has released a business update highlighting key developments and financial guidance for the upcoming fiscal year. Additionally, the company reaffirmed its revenue guidance and expressed confidence in achieving results at the upper end of the forecast range due to strong sales momentum and favorable reimbursement changes. A webinar is scheduled for today to discuss these updates in detail with the company's CEO and CFO.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Aroa Biosurgery
- Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
- Aroa Biosurgery H1 FY26 Results
- Appendix 4D and Half Year Report
- September 2025 Quarterly Report and Appendix 4C
- First clinical evidence published on AROA's ENIVO™ system for surgical dead space management.
Later from Aroa Biosurgery
- AROA Business Update Presentation
- Symphony Randomised Control Trial Complete
- ARX FY26 Preliminary Results
- FY26 Appendix 4E and Full Year Results
- FY26 Full Year Results Presentation
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery